177 related articles for article (PubMed ID: 25868140)
21. Pre-vaccination prevalence and genotype distribution of human papillomavirus infection among women from urban Tunis: a cross-sectional study.
Guettiti H; Ennaifer E; Attia L; Chelly D; Alaya NB; Aissa RB; Laassili T; Boubaker S
Asian Pac J Cancer Prev; 2014; 15(21):9361-5. PubMed ID: 25422225
[TBL] [Abstract][Full Text] [Related]
22. Awareness and knowledge about human papillomavirus among Inuit women in Nunavik, Quebec.
Cerigo H; Macdonald ME; Franco EL; Brassard P
J Community Health; 2011 Feb; 36(1):56-62. PubMed ID: 20517640
[TBL] [Abstract][Full Text] [Related]
23. Distribution of human papillomavirus types, cervical cancer screening history, and risk factors for infection in Manitoba.
Demers AA; Shearer B; Severini A; Lotocki R; Kliewer EV; Stopera S; Wong T; Jayaraman G
Chronic Dis Inj Can; 2012 Sep; 32(4):177-85. PubMed ID: 23046799
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with cervical cancer screening uptake among Inuit women in Nunavik, Quebec, Canada.
Cerigo H; Coutlée F; Franco EL; Brassard P
BMC Public Health; 2013 May; 13():438. PubMed ID: 23642072
[TBL] [Abstract][Full Text] [Related]
25. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
[TBL] [Abstract][Full Text] [Related]
27. Detection of human papillomavirus high-risk genotypes in rural women of Lucknow, North India.
Srivastava AN; Misra JS; Rizvi S
J Cancer Res Ther; 2021; 17(6):1468-1472. PubMed ID: 34916379
[TBL] [Abstract][Full Text] [Related]
28. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.
Insinga RP; Dasbach EJ; Elbasha EH; Liaw KL; Barr E
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):709-15. PubMed ID: 17416761
[TBL] [Abstract][Full Text] [Related]
29. Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer.
Castle PE; Rodríguez AC; Burk RD; Herrero R; Wacholder S; Hildesheim A; Morales J; Rydzak G; Schiffman M;
J Infect Dis; 2011 Mar; 203(6):814-22. PubMed ID: 21343148
[TBL] [Abstract][Full Text] [Related]
30. Type-specific persistence and associated risk factors of human papillomavirus infections in women living in central Italy.
Sammarco ML; Del Riccio I; Tamburro M; Grasso GM; Ripabelli G
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):222-6. PubMed ID: 23395560
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of high-risk human papillomavirus infection among women in Shaanxi province of China: A hospital-based investigation.
Cao D; Zhang S; Zhang Q; Wei X; Zhao M; Ma Q; Li Y; Wang L; Pei M; Yang T; Zhao J; Yang X
J Med Virol; 2017 Jul; 89(7):1281-1286. PubMed ID: 27935120
[TBL] [Abstract][Full Text] [Related]
32. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
Tiews S; Steinberg W; Schneider W; Hanrath C
J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.
Rodríguez AC; Schiffman M; Herrero R; Hildesheim A; Bratti C; Sherman ME; Solomon D; Guillén D; Alfaro M; Morales J; Hutchinson M; Katki H; Cheung L; Wacholder S; Burk RD
J Natl Cancer Inst; 2010 Mar; 102(5):315-24. PubMed ID: 20157096
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and risk factors of human papillomavirus infection types 16/18/45 in a cohort of French females aged 15-23 years.
Baudu A; Prétet JL; Riethmuller D; Chotard M; Mougin C; Mercier M
J Epidemiol Glob Health; 2014 Mar; 4(1):35-43. PubMed ID: 24534334
[TBL] [Abstract][Full Text] [Related]
35. Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial.
Ramanakumar AV; Naud P; Roteli-Martins CM; de Carvalho NS; de Borba PC; Teixeira JC; Blatter M; Moscicki AB; Harper DM; Romanowski B; Tyring SK; Ramjattan B; Schuind A; Dubin G; Franco EL;
BMJ Open; 2016 Aug; 6(8):e011371. PubMed ID: 27566633
[TBL] [Abstract][Full Text] [Related]
36. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
Zhao FH; Zhu FC; Chen W; Li J; Hu YM; Hong Y; Zhang YJ; Pan QJ; Zhu JH; Zhang X; Chen Y; Tang H; Zhang H; Durand C; Datta SK; Struyf F; Bi D;
Int J Cancer; 2014 Dec; 135(11):2604-11. PubMed ID: 24740547
[TBL] [Abstract][Full Text] [Related]
37. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
38. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
39. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women.
Trottier H; Mahmud SM; Lindsay L; Jenkins D; Quint W; Wieting SL; Schuind A; Franco EL;
Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):854-62. PubMed ID: 19223559
[TBL] [Abstract][Full Text] [Related]
40. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.
Rodríguez AC; Schiffman M; Herrero R; Wacholder S; Hildesheim A; Castle PE; Solomon D; Burk R;
J Natl Cancer Inst; 2008 Apr; 100(7):513-7. PubMed ID: 18364507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
